Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00584987 · ClinicalTrials.gov registry record · Phase 4
Intranasal Steroids and Oxymetazoline in Allergic Rhinitis
A Phase 4 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT00584987 is a Phase 4 study that has completed, run by University of Chicago. The registered enrollment target is 64 participants.
The verdict
NCT00584987, a Phase 4 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
We hypothesize that once daily use of oxymetazoline will not cause significant rhinitis medicamentosa and that the combination of fluticasone furoate plus oxymetazoline leads to faster relief of nasal congestion secondary to perennial allergic rhinitis than the use of fluticasone furoate alone.
Interventions
- DRUG Fluticasone furoate
- DRUG Oxymetazoline
- DRUG Placebo Fluticasone furoate
- DRUG Placebo Oxymetazoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00584987
The ClinicalTrials.gov registry entry for NCT00584987 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fluticasone furoate is the first listed.
NCT00584987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00584987 about?
NCT00584987 is a clinical study titled "Intranasal Steroids and Oxymetazoline in Allergic Rhinitis". We hypothesize that once daily use of oxymetazoline will not cause significant rhinitis medicamentosa and that the combination of fluticasone furoate plus oxymetazoline leads to faster relief of nasal congestion secondary to perennial allergic rhinitis than the use of fluticasone furoate alone.
What is the current status of trial NCT00584987?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2007-06. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00584987?
The interventions under investigation include: Fluticasone furoate (DRUG), Oxymetazoline (DRUG), Placebo Fluticasone furoate (DRUG), Placebo Oxymetazoline (DRUG).
Who is sponsoring clinical trial NCT00584987?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.